BioSpace News Archive

Simulations Plus, Inc., a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, announced that its shares of common stock have been approved for trading on The Nasdaq Global Select Market® effective as of the market open on Thursday, May 13, 2021, and will continue trading under its current ticker symbol SLP.

BioLargo, Inc., a developer of sustainable clean- technologies and full-service environmental engineering company, will host an investor webcast and conference call on Wednesday May 19, 2021, at 1:30 pm PT / 4:30 pm ET, open to the public.

Wearable Health Solutions, Inc., is pleased to announce that it is participating in, and has begun to ship product to a pilot program, with the Government of Bermuda, which will sell it’s iHelp Devices through a local dealer network to further grow it’s business in the country.

StageZero Life Sciences announced that it will release its First Quarter 2021operational results before market open on Monday, May 17, 2021.

An automated radiopharmaceutical production system iMiGiNE has been installed in Frederic Joliot Hospital in Orsay, France and commissioned in December 2020.

Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, recently expanded its patent portfolio to include the perioperative use of Qu’s SSIs to overcome immune dysfunction in patients undergoing cancer surgery.

Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced the presentation of updated blinded interim efficacy data from its ongoing Phase 2 RESCUE-ALS clinical trial.

Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection

Baudax Bio, Inc., a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, announced that Glass Lewis & Co. has recommended that Baudax Bio shareholders vote “FOR” Proposal 3, which seeks to amend the Company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares.

Matica Biotechnology, Inc. (Matica Bio) today announced that the Board of Directors has appointed Yun Jeong Song, MD, as the company’s new Chief Executive Officer (CEO) to continue its expansion as a CDMO supporting the global cell and gene therapy industry